Julio Chavez

Associate Professor

Moffitt Cancer Center

United States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (9)

Peter Riedell

University of Chicago

UNITED STATES

Luis Malpica

The University of Texas MD Anderson Cancer Center

UNITED STATES

Harsh Shah

Clinical Assistant Professor

Huntsman Cancer Institute

UNITED STATES

Jongphil Kim

Moffitt Cancer Center

UNITED STATES

Francine Foss

UNITED STATES

Piers Patten

King’s College London

UNITED KINGDOM

David Bond

Associate Professor

Ohio State University

UNITED STATES

Monalisa Ghosh

Assistant Professor

University of Michigan

UNITED STATES

Roberto Miranda

The University of Texas MD Anderson Cancer Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julio Chavez

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (9)

Peter Riedell

Luis Malpica

Harsh Shah

Jongphil Kim

Francine Foss

Piers Patten

David Bond

Monalisa Ghosh

Roberto Miranda

Make your next move.

Julio Chavez

Research Interests

Explore related searches

Contact this professor

Articles (20)

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management

Recent developments in CD19-targeted therapies for follicular lymphoma

Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review

CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies

Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study

Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy

Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma

Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience

Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study

EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management

Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions

The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma

Collaborators (9)

Peter Riedell

Luis Malpica

Harsh Shah

Jongphil Kim

Francine Foss

Piers Patten

David Bond

Monalisa Ghosh

Roberto Miranda

Make your next move.